These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 33421995)

  • 1. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes.
    Talbot J; Stuckey R; Crawford L; Weatherby S; Mullin S
    J Headache Pain; 2021 Jan; 22(1):5. PubMed ID: 33421995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
    Eghtesadi M; Leroux E; Pagé G
    Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
    Pensato U; Baraldi C; Favoni V; Cainazzo MM; Torelli P; Querzani P; Pascazio A; Mascarella D; Matteo E; Quintana S; Asioli GM; Cortelli P; Pierangeli G; Guerzoni S; Cevoli S
    Neurol Sci; 2022 Feb; 43(2):1273-1280. PubMed ID: 34224026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
    Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
    Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
    Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
    Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
    Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
    J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study.
    Cainazzo MM; Baraldi C; Ferrari A; Lo Castro F; Pani L; Guerzoni S
    Neurol Sci; 2021 Oct; 42(10):4193-4202. PubMed ID: 33547541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
    Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective real-world analysis of erenumab in refractory chronic migraine.
    Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
    J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.
    Troy E; Shrukalla AA; Buture A; Conaty K; Macken E; Lonergan R; Melling J; Long N; Shaikh E; Birrane K; Tomkins EM; Goadsby PJ; Ruttledge MH
    J Headache Pain; 2023 Jan; 24(1):5. PubMed ID: 36647006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
    Giannouchos TV; Mitsikostas DD; Ohsfeldt RL; Vozikis A; Koufopoulou P
    Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between response to triptans and response to erenumab: real-life data.
    Frattale I; Caponnetto V; Casalena A; Assetta M; Maddestra M; Marzoli F; Affaitati G; Giamberardino MA; Viola S; Gabriele A; Pistoia F; Cerone D; Marini C; Sacco S; Ornello R
    J Headache Pain; 2021 Jan; 22(1):1. PubMed ID: 33407070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
    J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
    Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
    J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
    Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.
    Guerzoni S; Baraldi C; Pensato U; Favoni V; Lo Castro F; Cainazzo MM; Cevoli S; Pani L
    Neurol Sci; 2022 Jun; 43(6):3823-3830. PubMed ID: 35015202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis.
    Armanious M; Khalil N; Lu Y; Jimenez-Sanders R
    J Pain Palliat Care Pharmacother; 2021 Mar; 35(1):1-6. PubMed ID: 33125303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.